Eurofarma is a multinational with 100% Brazilian capital, with over 44 years of history, recognized by the medical community and the society for promoting access to health and quality of life with treatments at the right price, quality and innovation.

With operations in more than 20 countries in South and Central America, in the Caribbean and Africa, it has 12 manufacturing plants installed, strategically located in Latin America, positioning especially in the major pharmaceutical segments: Prescribing, Exempt Prescription Drugs, Generics, Hospital , Bidding, Oncology, Third Party Services and Veterinary. The company has a broad portfolio that meets all medical specialties and is a reference in the central nervous system, anti-infective and hormonal drugs.

Recognized for its pioneering and entrepreneurial vocation from the beginning of its activities 44 years ago, originally as Billi Farmacêutica, it operates with national and international partnerships in different models of cooperation such as licenses, distribution agreements, providing services in the productive area, with joint ventures, co-development, among others. With a focus on innovation, the company accounts for about 150 projects in its pipeline and expansion plans for key global markets.

Eurofarma values as its most important asset of human capital. The Group has approximately 6,500 employees, including more than 5,000 in Brazil. It also has the largest sales force and market medical advertisement, with about 2,800 employees who visit approximately 600 thousand doctors per month.

Elected for more than a decade among the best companies to work for, it has been placed for 10 years in the ranking of the “Best Companies to Work For” by Exame Voce S/A magazine, and three consecutive years in the “Época GPTW” ranking (Great Place to Work )”.

Only pharmaceutical company twice champion by the Exame Sustainability Guide, consolidated its adherence to the UN Global Compact in 2015, committing to follow in their activities those 10 principles of the document set out by the United Nations Organizations. The initiative calls for the adoption of business practices based on ethical and responsible values in the areas of environment, human rights, labor relations and fighting corruption.

Social investments of the company are conducted by the Eurofarma Institute, founded 10 years ago. The projects directly benefit more than 43,000 people, primarily in the areas of continuing education, environmental and training of young people.

As a company of solid values, which grows sustainably, it seeks excellence and feeds on challenges, taking further steps as if they were the first ones.

Controlled Companies and Joint Ventures

The Eurofarma Group covers the Eurofarma Controller (Eurofarma Laboratories S.A.) and Eurofarma Consolidated, which includes the different company’s business, such as joint ventures and other Group companies.

Built in 2013, it is an independent operation owned in 100% to Eurofarma. Dedicated to the production and commercialization of the brand products, focusing on the medical prescription area, mostly for the Psychiatry, Gynecology and Respiratory System specialties. It provides production service for Eurofarma and other laboratories, accounting for the entire line of the company antibiotics (penicillin, cephalosporin and carbapenem).

Responsible for the analysis of samples for relative bioavailability studies and bioequivalence studies, required for obtaining drug registration at Anvisa. The company also undertakes residual cleaning validation tests and stability studies, besides being a Research Center.

Click here to access www.magabi.com.br

A joint venture created in 2010 between Eurofarma, which holds 50% of the company, and the Hertape Animal Health group for the production of vaccines against FMD. Headquartered in Juatuba (MG), the company focuses on the production and quality control activities, while the marketing of vaccines is made directly by the sales force of the company shareholders.

A joint venture formed in 2012 by Eurofarma, Cristália and Merck Sharp & Dohme (MSD). It promotes and distributes medical prescription products.

A Joint venture between Eurofarma, which holds 50% stake, and the Biolaboratory. Founded in 2012 to operate in the development of production of biosimilar medications.

Time Line

Trajectory

Founded in 1972 with the name of Billi Pharmaceuticals, the proposed business was completely innovative in the industry, but already anticipated a trend of today’s world: outsourcing. No own products, Billi was born with the aim of manufacturing products for other domestic and foreign laboratories.

This was the first seed. Over time, and with investments in innovation and development, employee training and management focused on efficiency, quality of its products and customer satisfaction, the company grew, acquired other laboratories and expanded its scope of action, starting to produce and market own brands and under license from multinationals.

As a result of this development, in 1993 the company adopted the name Eurofarma and, since then, has seen a strong growth. In 2005, its sales reached R$ 745 million. Five years later, the total revenue rose about 74% to $ 1.3 billion.

Markets in Brazil and Latin America act as an important opportunity for Eurofarma. In 2009, Eurofarma began its internationalization project, a milestone in its history, with the acquisition of Argentine Quesada Pharmaceutics. Since then, the company has been working hard on integrating the operations of this subsidiary, which, in July 2010, began to act under the corporate name of Eurofarma Argentina.

In 2010, it entered new markets through investments in clinical research, biotechnology and acquisition in the domestic market, aiming to become one of the three largest pharmaceutical companies in the country. In the same year, continuing its goal of internationalization, the company acquired the Laboratories Gautier, Uruguay, with a presence in Bolivia, and Chile’s Volta – including Farmindustria, a company from the same group.

The company continued with this strategy in 2011, submitting products dossiers and obtaining records for medications in the countries in which it operates, this time in the Venezuelan market, the third largest one in Latin America. It invested in infrastructure, in the creation of a new company and in the integration between subsidiaries and headquarters. Among many other accomplishments and learnings, it has also celebrated the five-year anniversary of the Institute that bears its name.

In 2012, Eurofarma turned 40 years with the creation and reformulation of strategic areas of the company and continued its internationalization process, important steps towards the goal of becoming a large multinational company, starting its operations in Colombia, through the purchase of a pharmaceutical manufacturing plant of Merck Sharp & Dohme (MSD). Initially, the production would be unique in providing services to third parties and MSD.

The following year, in 2013, Eurofarma acquired Refasa Carrión, present for 57 years in Peru and Laprin – 4th company in medical prescription in the market of Guatemala, and that also maintains operations in Panama, Nicaragua, Honduras. El Salvador, Costa Rica and the Dominican Republic.

In 2014, it began its commercial operations in Colombia and the acquisition of the minority stake in Chile. Offices were also opened in Venezuela, Paraguay and Ecuador for the submission of dossiers. Thus, the organization started to cover 68.6% of the Latin American market. With an established presence with own operations in 20 countries in South and Central America, in the Caribbean and Africa. in 2014, the company completed the negotiation, becoming a shareholder in the North American Melinta Therapeutics and made commercial agreements with leading companies in South Korea (Don-A) and Sri Lanka (Ceyoka).

Now in 2015, after 9 years of study, researchers at Eurofarma conquered the record of the first biosimilar medicine in Latin America, Fiprima® (filgrastim) used to induce an increase in the body’s defense cells, in patients with some types of cancer. Worldwide, there are only 20 biosimilars.

Continuing its expansion process towards global markets, 2016 begins with the opening of a new office in Mozambique, which marks the company’s entry into the African market. It consolidates its presence in Central America and in the Caribbean, with the opening of the market in Belize.

Mission

To promote the access to health and quality of life with treatments at a fair price in a profitable operation that ensures its sustainable growth in the different market segments of the company.

Vision

To consolidate operations in Latin America and expand into key global markets seeking recognition of physicians and communities by the launch of new products and profitability that allows the company's sustainable growth.

Values

SEE ALL VALUES